Servier buys PIXUVRI Non-Hodgkin lymphoma therapy from CTI BioPharma
Category: #health  By Saipriya Iyer  Date: 2019-10-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Servier buys PIXUVRI Non-Hodgkin lymphoma therapy from CTI BioPharma

A substantial rise in occurrence of cancer cases is being witnessed across the globe lately. Various global pharmaceutical firms are increasingly working towards discovering novel, innovative treatments that effectively address cancer growth to minimize the effect the disease has on people’s lives. These drug discovery efforts in the pharmaceutical sector are typically fueled through acquisitions and collaborations.

Servier, a global pharmaceutical firm headquartered in Neuilly-sur-Seine, France, reportedly announced the acquisition of PIXUVRI®, a non-Hodgkin B-cell lymphoma treatment, from Seattle based biopharmaceutical firm, CTI BioPharma.

PIXUVRI is a therapy for adult patients with multiple refractory or relapsed aggressive Non-Hodgkin B-cell lymphoma. CTI Biopharma and Servier signed an Asset Purchase Agreement, according to which the global rights for PIXUVRI have been transferred to Servier.

Servier commercialized PIXUVRI across the globe, in all nations where this drug was authorized for distribution under exclusive license from the American pharmaceutical firm.

Executive VP, Global Head of R&D of Servier, Claude Bertrand stated that the PIXUVRI acquisition is a crucial step towards the company’s long-term strategy of becoming an important player in oncology. In oncology, one of the prime focuses of the firm is hematology, and now the firm has two medicines which are globally marketed along with an innovative and strong pipeline of the drug candidates including CAR-T therapies.

Bertrand further added that as a part of the company strategy, Servier is committed at investing 50% of its R&D budget in the oncology field.

Non-Hodgkin lymphoma (NHL) is a type of blood cancer which affects lymphatic system, it could occur in various body parts from the lymph nodes present in the neck to the spleen or the liver, but it can also occur in other organs like the small bowel, stomach, brain, bones, skin or testicles.

Globally there are more than 500,000 new cases of Non-Hodgkin lymphoma per year. NHL is both the world’s 11th most commonly detected cancer as well as a common cause of deaths due to cancer.

VP, Global Head of Business Development & Licensing, Servier, Eric Falcand stated that the company has a strong commitment to offer effective solutions for patients with cancer. PIXUVRI lymphoma treatment is an effective cancer therapy, it has received standard marketing authorization earlier in June from the European Medicines Agency, and now to achieve long term goals of Servier, the company assures that patients will have easy access to PIXUVRI.

 

Source credit: https://www.businesswire.com/news/home/20190930005875/en/Servier-acquires-non-Hodgkin-B-cell-lymphoma-treatment-PIXUVRI%C2%AE



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Nestlé acquires Allergan’s Zenpep to expand medical nutrition business
Nestlé acquires Allergan’s Zenpep to expand medical nutrition business
By Saipriya Iyer

Nestle, a Swiss food and beverage giant, has recently expanded its medical nutrition business by entering an asset purchase agreement to acquire Allergans Zenpep, for undisclosed sum. Nestle will take ownership of Z...

Nestle introduces three new flavors of the beloved Smarties Buttons
Nestle introduces three new flavors of the beloved Smarties Buttons
By Saipriya Iyer

 

  • The company has introduced three new Smarties Buttons flavors hitting stores this week
  • Smarties Buttons will be available in mouth-w...

New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
By Saipriya Iyer

Medtronic plc, a renowned US-based medical device company, reportedly announced that its Micra AV pacemaker has received approval from the U.S. FDA. The Medtronic Micra AV is the world’s smallest pacemaker with A...